| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 04/29/2010 | US20100104632 Drug Having Regulatory Cell Ligand Contained in Liposome |
| 04/29/2010 | US20100104630 Water soluble statin microstructures and method of preparation |
| 04/29/2010 | US20100104629 Cationic lipids and uses thereof |
| 04/29/2010 | US20100104628 method of treating neuroblastoma |
| 04/29/2010 | US20100104626 Methods and compositions for treating and diagnosing kidney disease |
| 04/29/2010 | US20100104625 Biodegradable compositions and materials |
| 04/29/2010 | US20100104624 Combination therapy using phosphodiesterase inhibitors |
| 04/29/2010 | US20100104621 Treating adhd and other diseases involving inflammation |
| 04/29/2010 | US20100104620 Over-coated product including tableted center and medicament |
| 04/29/2010 | US20100104618 Polymer-based surgically implantable haloperidol delivery systems and methods for their production and use |
| 04/29/2010 | US20100104614 Providone compositions for wound healing |
| 04/29/2010 | US20100104590 Alpha-galactosylceramide derivatives, pharmaceutically acceptable salts thereof, preparation method and pharmaceutical composition for the immune adjuvant containing the same as an active ingredient |
| 04/29/2010 | US20100104587 Methods of modulating the negative chemotaxis of immune cells |
| 04/29/2010 | US20100104585 Methods and Reagents for Regulation of Cellular Responses in Biological Systems |
| 04/29/2010 | US20100104584 Genes involved in mitochondrial biogenesis |
| 04/29/2010 | US20100104583 Gene Polymorphisms in VEGF and VEGF Receptor 2 as Markers for Cancer Therapy |
| 04/29/2010 | US20100104581 Methods for Diagnosing and Treating Graft Rejection and Inflammatory Conditions |
| 04/29/2010 | US20100104579 Trex1 as a marker for lupus erythematosus |
| 04/29/2010 | US20100104578 Method and composition for treatment of neoplasms |
| 04/29/2010 | US20100104570 Semaphorin 7A Plays a Critical Role in TGF-Beta1-Induced Pulmonary Fibrosis and Alveolar Destruction |
| 04/29/2010 | US20100104567 Pharmaceutical composition |
| 04/29/2010 | US20100104565 Combinations comprising dmxaa for the treatment of cancer |
| 04/29/2010 | US20100104561 TYROSINE-MODIFIED RECOMBINANT rAAV VECTOR COMPOSITIONS AND METHODS FOR USE |
| 04/29/2010 | US20100104558 Use of an EGFR Antagonist for the Treatment of Glomerolonephritis |
| 04/29/2010 | US20100104555 HCV neutralizing epitopes |
| 04/29/2010 | US20100104554 Peptide and uses thereof |
| 04/29/2010 | US20100104552 Antibiotic synergism |
| 04/29/2010 | US20100104549 Glufosfamide combination therapy |
| 04/29/2010 | US20100104548 Modulation of amino acid metabolism in the hypothalamus |
| 04/29/2010 | US20100104546 Modulators of antigen-dependent t cell proliferation |
| 04/29/2010 | US20100104541 Method for Preventing and Treating Cardiovascular Diseases with BRCA1 |
| 04/29/2010 | US20100104540 Methods and compositions for treatment of fibrosis |
| 04/29/2010 | US20100104537 Methods of treating Parkinson's disease using viral vectors |
| 04/29/2010 | US20100104534 Hydrazido-peptides as inhibitors of hcv ns3-protease |
| 04/29/2010 | US20100104533 Early intervention of viral infection with immune activators |
| 04/29/2010 | US20100104532 Nucleoside analogs for antiviral treatment |
| 04/29/2010 | US20100104529 TNF-alpha VACCINE FOR TREATING DISEASE CONDITIONS MEDIATED BY PATHOLOGICAL TNF-alpha |
| 04/29/2010 | US20100104527 Treating hyperkalemia with crosslinked cation exchange polymers of improved physical properties |
| 04/29/2010 | US20100104522 Compostion for skin external use containing omega-3 fatty acid |
| 04/29/2010 | US20100104515 Use of alpha-hydroxy carbonyl compounds as reducing agents |
| 04/29/2010 | US20100104512 Dendritic Chelated Compounds, Methods for Making the Same and Pharmaceutical Compositions Containing the Same |
| 04/29/2010 | US20100104507 Use of sterically stabilized cationic liposomes to efficiently deliver cpg oligonucleotides in vivo |
| 04/29/2010 | US20100104506 Nanoparticle-Coated Medical Devices And Formulations For Treating Vascular Disease |
| 04/29/2010 | US20100104504 Materials and methods for diagnosis, prevention and/or treatment of stress disorders and conditions associated with abeta peptide aggregation |
| 04/29/2010 | DE4035442B4 Arzneimittel enthaltend als Wirkstoff R-α-Liponsäure A medicament comprising as an active ingredient R-α-lipoic acid |
| 04/29/2010 | DE19823940B4 Enterische Fluoxetinpellets Enteric Fluoxetinpellets |
| 04/29/2010 | DE102009004436A1 Verwendung einer Tirucallensäure, einer Lupansäure oder einer Robursäure als Arzneimittel Using a Tirucallensäure, a Lupansäure or Robur acid as a drug |
| 04/29/2010 | DE102008053044A1 Composition, useful for preventing and/or treating renal dysfunction, preferably renal failure, comprises combination of calcium salt as first active component, and magnesium salt, as second active component |
| 04/29/2010 | CA2751761A1 Treatment and/or prevention of inner ear conditions by modulation of a metabotropic glutamate receptor |
| 04/29/2010 | CA2742042A1 Modulators of cystic fibrosis transmembrane conductance regulator |
| 04/29/2010 | CA2741718A1 Modulators of cystic fibrosis transmembrane conductance regulator |
| 04/29/2010 | CA2741683A1 Platinum acridine anti-cancer compounds and methods thereof |
| 04/29/2010 | CA2741599A1 Method of synthesizing macrolide compounds |
| 04/29/2010 | CA2741554A1 Nutritional composition to promote healthy development and growth |
| 04/29/2010 | CA2741490A1 Therapeutics for neurological disorders |
| 04/29/2010 | CA2741428A1 Azaindole derivatives |
| 04/29/2010 | CA2741413A1 Novel uses |
| 04/29/2010 | CA2741368A1 Compositions comprising 4-(2-(5-bromo-4-(1-cyclopropylnaphthalen-4-yl)-4h-1,2,4-triazol-3-ylthio) acetamido)-3-chlorobenzoic acid and pharmaceutically acceptable salts thereof |
| 04/29/2010 | CA2741349A1 Pyrimidine and triazine sulfonamide derivates as b1 bradykinin receptor (b1r) inhibitors for treating pain |
| 04/29/2010 | CA2741313A1 Substituted pyrazolo[1,5-a]pyrimidine compounds as trk kinase inhibitors |
| 04/29/2010 | CA2741312A1 Combination therapy with peptide epoxyketones |
| 04/29/2010 | CA2741306A1 Fosfomycin/tobramycin combinations for the treatment and prevention of ophthalmic, otological and dermatological infections |
| 04/29/2010 | CA2741294A1 5' and 2' bis-substituted nucleosides and oligomeric compounds prepared therefrom |
| 04/29/2010 | CA2741288A1 Ophthalmic compositions useful for improving visual acuity |
| 04/29/2010 | CA2741204A1 Double-stranded ribonucleic acids with rugged physico-chemical structure and highly specific biologic activity |
| 04/29/2010 | CA2741189A1 Transition metal complexes of bis[thiohydrazide amide] compounds |
| 04/29/2010 | CA2741178A1 Solid forms of n-(4-(7-azabicyclo[2.2.1]heptan-7-yl)-2-(trifluoromethyl)phenyl)-4-oxo-5-(trifluoromethyl)-1,4-dihydroquinoline-3-carboxamide |
| 04/29/2010 | CA2741126A1 Fused heterocyclic m1 receptor positive allosteric modulators |
| 04/29/2010 | CA2741125A1 Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
| 04/29/2010 | CA2741107A1 Biscuit comprising guar gum |
| 04/29/2010 | CA2741089A1 Modulation of axon degeneration |
| 04/29/2010 | CA2741078A1 Arformoterol and tiotropium compositions and methods for use |
| 04/29/2010 | CA2741030A1 Low molecular weight thyroid stimulating hormone receptor (tshr) agonists |
| 04/29/2010 | CA2741028A1 Composition for treatment of epithelial tissue |
| 04/29/2010 | CA2740982A1 Pyridine derivatives substituted with heterocyclic ring and y-glutamylamino group, and antifungal agents containing same |
| 04/29/2010 | CA2740970A1 Naphthamides as anticancer agents |
| 04/29/2010 | CA2740952A1 Compounds for treating ophthalmic diseases and disorders |
| 04/29/2010 | CA2740855A1 Nutritional composition with anti-regurgitation properties |
| 04/29/2010 | CA2740810A1 Phenanthroindolizidine compound and nf.kappa.b inhibitor containing same as active ingredient |
| 04/29/2010 | CA2740807A1 Phenanthroindolizidine derivative and nf.kappa.b inhibitor containing same as active ingredient |
| 04/29/2010 | CA2740722A1 Salts of isobutyric acid (1 r*, 2r*, 4r* ) -2- (2-{ [3- (4, 7-dimeth0xy-1 h-benzoimidazol-2-yl) -propyl] -methyl-amino } -ethyl) -5-phenyl-bicyclo [2.2.2] oct-5- en- 2 -yl |
| 04/29/2010 | CA2740659A1 Novel compound containing vanillin and ethylvanillin, and preparation and applications thereof |
| 04/29/2010 | CA2740616A1 Sulphone-substituted anilinopyrimidine derivatives as cdk inhibitors, their preparation and use as medicaments |
| 04/29/2010 | CA2740476A1 Stable tablet containing 4,5-epoxymorphinan derivative |
| 04/29/2010 | CA2740430A1 Bridged tetrahydronaphthalene derivatives |
| 04/29/2010 | CA2740366A1 Aryl gpr120 receptor agonists and uses thereof |
| 04/29/2010 | CA2740364A1 Tetrahydronaphthalene compounds |
| 04/29/2010 | CA2740313A1 Crystalline forms of (r) -5- [3-chloro-4- ( 2, 3-dihydroxy-propoxy) -benz [z] ylidene] -2- ( [z] -propylimino) -3-0-tolyl-thiazolidin-4-one |
| 04/29/2010 | CA2740001A1 Urea-based film-forming solution for treating nail psoriasis |
| 04/29/2010 | CA2739946A1 Isoquinolinone derivatives as nk3 antagonists |
| 04/29/2010 | CA2739927A1 Disubstituted azepan orexin receptor antagonists |
| 04/29/2010 | CA2739917A1 2,5-disubstituted morpholine orexin receptor antagonists |
| 04/29/2010 | CA2739916A1 2,5-disubstituted piperidine orexin receptor antagonists |
| 04/29/2010 | CA2739895A1 Compositions and methods for inhibiting expression of transthyretin |
| 04/29/2010 | CA2739882A1 Pharmaceutical composition improving intestinal absorption |
| 04/29/2010 | CA2739740A1 Substituted 4,5,6,7-tetrahydrothienopyridines as kcnq2/3 modulators for treating pain, epilepsy and urinary incontinence |
| 04/29/2010 | CA2739739A1 Sulfoximine-substituted anilino-pyrimidine derivatives as cdk inhibitors, production and use thereof as medicinal products |
| 04/29/2010 | CA2738957A1 Methods for treating eye disorders |
| 04/29/2010 | CA2738807A1 Treatment of neuroblastoma with multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin |
| 04/29/2010 | CA2738453A1 Urea derivatives of substituted nortropanes, medicaments containing such compounds and their use |